SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Izzy who wrote (4359)5/20/1998 11:50:00 PM
From: PAL  Read Replies (1) of 6136
 
Izzy, You are already know about supply and demand. One of the important component of the price of a stock is how well the demand is. This means the underwriter of the stock, the public relations, the promotions of the company to get the market to drool over the prospect of the company. ENMD was nothing in November, but then a few weeks ago, a journalist from NYT reported that same story on the front page. That was the break. Even AGPH came on CNBC and promoted AG3340 on Phase II/III. But then it seems there is no follow up. Have you heard anything on AGPH from that LA conference?

Brokerage firms make money by buying and selling for funds and underwrites secondary offerings, involved in mergers etc. If a company does that often, it becomes the darling of WS. Example: AOL. In addition AOL has the numero uno PR dept. Now if AGPH has Wally Amos as PR, it might be different. Unfortunately, scientists are from a good PR person.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News